Tirzepatide vs Retatrutide
Compare the research profiles of Tirzepatide and Retatrutide. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesTirzepatide
Tirzepatide (Mounjaro/Zepbound)
Category
weight-loss
Research Level
Phase 4 (Post-Market)
FDA Status
approved
Retatrutide
Retatrutide (LY3437943)
Category
weight-loss
Research Level
Phase 3 Clinical Trials
FDA Status
clinical-trials
Detailed Comparison
| Aspect | Tirzepatide | Retatrutide |
|---|---|---|
| Overview | A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Shows superior weight loss results compared to semaglutide in trials.... | A triple hormone receptor agonist (GLP-1/GIP/Glucagon) in clinical trials by Eli Lilly. Shows remarkable weight loss results up to 29% body weight. Often misleadingly called "GLP-3" on gray market.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Activates both GIP and GLP-1 receptors, providing dual hormone action. This combination may provide enhanced metabolic benefits compared to GLP-1 alon... | Activates three receptors simultaneously: GLP-1, GIP, and glucagon. The glucagon component may provide additional metabolic benefits and fat burning.... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.